Pandey Himani, Tang Daryl W T, Wong Sunny H, Lal Devi
Redcliffe Labs, Electronic City, Noida 201301, India.
School of Biological Sciences, Nanyang Technological University, Singapore 308232, Singapore.
Cancers (Basel). 2023 Jan 30;15(3):866. doi: 10.3390/cancers15030866.
Colorectal cancer (CRC) is the second-leading cause of cancer-related deaths worldwide. While CRC is thought to be an interplay between genetic and environmental factors, several lines of evidence suggest the involvement of gut microbiota in promoting inflammation and tumor progression. Gut microbiota refer to the ~40 trillion microorganisms that inhabit the human gut. Advances in next-generation sequencing technologies and metagenomics have provided new insights into the gut microbial ecology and have helped in linking gut microbiota to CRC. Many studies carried out in humans and animal models have emphasized the role of certain gut bacteria, such as , enterotoxigenic , and colibactin-producing , in the onset and progression of CRC. Metagenomic studies have opened up new avenues for the application of gut microbiota in the diagnosis, prevention, and treatment of CRC. This review article summarizes the role of gut microbiota in CRC development and its use as a biomarker to predict the disease and its potential therapeutic applications.
结直肠癌(CRC)是全球癌症相关死亡的第二大原因。虽然CRC被认为是遗传和环境因素相互作用的结果,但有几条证据表明肠道微生物群参与促进炎症和肿瘤进展。肠道微生物群是指栖息在人类肠道中的约40万亿个微生物。下一代测序技术和宏基因组学的进展为肠道微生物生态学提供了新的见解,并有助于将肠道微生物群与CRC联系起来。在人类和动物模型中进行的许多研究都强调了某些肠道细菌,如产肠毒素的、产大肠杆菌素的,在CRC发病和进展中的作用。宏基因组学研究为肠道微生物群在CRC诊断、预防和治疗中的应用开辟了新途径。这篇综述文章总结了肠道微生物群在CRC发展中的作用及其作为预测疾病的生物标志物的用途及其潜在的治疗应用。